Wecare Probiotics Successfully Approved for National Post-Doctoral Research Station Independent Status

SUZHOU, China – May 14, 2025 – Wecare Probiotics (Suzhou) Co., Ltd., a national high-tech enterprise integrating the research and development, production, and application of probiotic strains, has successfully received approval to upgrade its post-doctoral research station to independent status.

Established initially as a post-doctoral research station branch in 2018, the elevation to an independent station is a significant recognition of Wecare's robust scientific capabilities and its commitment to fostering high-level research talent.

This achievement is underpinned by Wecare's extensive R&D infrastructure, which includes a vast repository of over 30,000 proprietary probiotic strains and seven specialized research institutes, notably the Probiotic Strain Process Research Institute. Wecare has built a comprehensive professional R&D platform known as "One Academy, Two Stations, Three Centers" and has established joint post-doctoral training programs with renowned academic institutions like Soochow University and Jiangnan University.

The company's dedication to innovation is further demonstrated by its formidable R&D team, comprising 3 specially appointed academicians, 8 chief scientists, over 10 doctoral degree holders, and more than 100 R&D and application engineers. This elite team is supported by substantial investment, with R&D expenditures exceeding 350 million RMB over the past three years.

The approval for an independent national post-doctoral research station is expected to significantly enhance Wecare's capacity to attract top scientific talent, accelerate groundbreaking research in the probiotics field, and solidify its position as a leader in global probiotic innovation.